Patients undergoing allogeneic bone marrow transplants (BMT) are often malnourished prior to commencing the procedure. They face intensive treatment with often marked nutritional consequences. There is no consensus on the optimal nutritional management of these patients. Elective parenteral nutrition (PN), beginning pre-transplant irrespective of the patients nutritional status, or the use of 'salvage' PN, beginning during the post-transplant period if the patient fails to maintain nutritional status with oral diet, have been used. Enteral nutrition may benefit the patient by maintaining nutritional support throughout the transplant period, avoiding the complications and expense of PN and possibly, by using specific diets, protecting the gastrointestinal tract from the effects of chemoradiation. However, naso-gastric feeding during a transplant is not without risks, including the safe insertion of a tube in patients with mucositis and pan-cytopenias, tube displacement by vomiting and aspiration from gastro-oesophageal reflux. An alternative approach is to use nasojejunal (NJ) feeding tubes which are associated with less risk of loss due to vomiting and less risk of aspiration. We report a pilot study of 15 allogeneic BMT patients who had elective NJ feeding initiated before conditioning therapy irrespective of perceived nutritional compromise. This was well tolerated and feasible with a motivated nutritional team. Bone Marrow Transplantation (2001) 28, 1135-1139. Keywords: allogeneic bone marrow transplant; enteral feeding; naso-jejunal feeding tubes; pilot study Patients undergoing BMT are often under-nourished due to previous chemotherapy and the underlying disease process. They face a long hospital stay and intensive conditioning therapy, which can have marked nutritional consequences. Subsequent complications such as infections, veno-occlus-
ive disease and graft-versus-host disease add to the catabolic demands on the body.
Intestinal complications such as mucositis (damaged oral and pharyngeal mucosa) and enteropathy (damage to the rapidly dividing cells of the small bowel) are a major cause of morbidity and mortality following conditioning chemoradiotherapy. 1 Patients often experience severe nausea, vomiting and anorexia. Mucositis is painful, making eating and even drinking difficult. Enteropathy results in malabsorption, secretory diarrhoea and protein loss. 2 A loss of barrier function contributes to translocation of gut bacteria into the bloodstream and often life-threatening infections can ensue. 3 As a consequence, many patients experience dramatic weight loss, delayed recovery times and prolonged hospital stays.
There are well-recognised problems associated with nutritional support in BMT patients. PN is often difficult to maintain in patients because of sepsis, abnormal liver function and volume restrictions. PN has also been shown to be associated with an increased risk of sepsis 4 and to result in mucosal atrophy. 5 Naso-gastric feeding has not been utilised in BMT patients for a number of reasons. It is difficult to pass NG tubes in patients with established mucositis and there is a perceived risk of perforation, bleeding and aspiration associated with their use. NG feeding itself can also provoke vomiting which can result in the loss of both feed and tube.
Our unit's approach to nutritional support during BMT has been to monitor weight loss and initiate 'salvage' PN if required. If a patient is felt to be malnourished prior to conditioning we use fortified, supplemented oral diet or, rarely, PN. In an attempt to reduce bacterial translocation and limit GVHD, all patients receive oral broad-spectrum antibiotics. 6 Several new concepts in the way that enteral diet affects mucosal turnover and integrity have led us to question our practice.
Elemental diets have been shown to protect the gut against the effects of chemoradiation, possibly by reducing cell turnover at the time of conditioning. [7] [8] [9] [10] The mucosa receives much of its nutrition directly from the lumen and substrates such as glutamine and short chain fatty acids have been shown to be the preferred fuels for the enterocytes and colonocytes, respectively. 11, 12 Glutamine supplemented elemental diets have been shown to have beneficial effects in terms of intestinal mucosal morphology and bacterial translocation following radiotherapy. [13] [14] [15] [16] Gastrointestinal tract damage, the release of inflammatory cytokines and the translocation of lipopolysaccharide across the GI barrier are known to be important mediators of GVHD. The protection of the GI tract may therefore be important in modulating the inflammatory amplification of GVHD. 17 Clearly, the possibility of protecting the gut from damage by chemoradiation during BMT and of impacting on the subsequent development of GVHD needs further study. It is important to determine if an advantage can be gained by altering the route, timing, and composition of nutritional support in BMT recipients. In order for such work on a BMT-specific diet to go ahead, reliable and easily maintained access to the GI tract is required. The new smaller bore, coiled NJ tubes being produced are more acceptable to the patients and are said to be associated with less risk of loss due to vomiting, and less risk of aspiration.
A pilot study was therefore set up to determine if nasojejunal access could be established and maintained in BMT patients, and whether such patients could tolerate the restrictions of a non-oral enteral diet.
Patients and methods

Patients
A total of 15 patients undergoing allogeneic bone marrow transplants between September 1998 and October 1999 were recruited into this pilot study irrespective of nutritional status. Local ethical committee approval was gained prior to the onset of the study and informed consent was obtained from the patients. Table 1 summarises patient characteristics.
Transplant conditioning
Sibling and MUD transplants received cyclophosphamide (60 mg/m 2 ϫ 2 days) and TBI (12 Gy in six fractions for sibling BMT and 14.4 Gy in six fractions for unrelated donor BMT). In addition, patients undergoing unrelated donor BMT received pre-transplant ATG or Campath 1G as previously described. 18 Cyclosporine A and methotrexate were used as GVHD prophylaxis.
Naso-jejunal tube insertion and feeding
A Bengmark self-propelling feeding tube 19 was sited in the jejunum under radiographic control by a skilled operator at day Ϫ6/Ϫ7 pre-transplant. The study protocol involved feeding until the day of engraftment (ANC Ͼ0.5 ϫ 10 9 /l) when the tube was to be removed.
Caloric requirements were calculated using the Schofield equation with activity and stress correction factors. 20 Nitrogen was given at 0.17-0.2 g/kg/day. The feed formula used was Emsogen (Scientific Hospital Supplies, Liverpool, UK) which is a peptide medium-chain triglyceride-based feed. Glutamine to 25% of total calculated nitrogen requirements was added from day ϩ7. The feed was commenced at 30 ml/h and increased over 3 days to meet estimated requirements. Tubes were flushed at 6 h intervals with sterile water but if diarrhoea was a problem, the flushes were changed to normal saline. Oral intake was limited to water.
Outcome measures
The fate of the tube and its complications, patient acceptance and weight and survival at discharge, and at 3 and 6 months post transplant, were chosen as outcome measures.
Statistical methods
Mann-Whitney U statistical methods were applied. Table 1 and Figure 1 highlight the fates and complications of the tubes. Eight out of 15 patients retained their tubes until the day of engraftment. One patient refused to have a tube inserted despite giving initial consent. Four of the 15 patients lost their tubes during conditioning and the early transplant period because of forceful vomiting. Two of these had tubes resited but they were again lost because of vomiting. A further two patients lost their tubes at day +5, one due to accidental removal and the other due to kinking in the tube which could not be corrected.
Results
Fate and complications of the tube
Only one patient was poorly tolerant of the tube, and in fact they lost their tube at day ϩ2 because of vomiting. All the other patients tolerated the tube placement and NJ feeding without additional oral intake. One patient had epistaxis on the side of the tube and another on the opposite side. Three patients had problems with vomiting a loop of the tube but this was rectified by fixing the tube at the cheek rather than at the nose. Two patients needed to have the rate of feeding reduced because of diarrhoea. Tubes were in place for a varied period of time from 0 to 34 days (mean 16 days) and eight patients received some degree of glutamine supplementation, ie their tubes were still in situ at day +7 and after.
Weight loss
Weight loss was measured by the percentage of body weight lost (BWL). Patients who retained their tubes until engraftment, and therefore received prolonged NJ feeding, were compared to those who had lost their tubes by day ϩ5 and so received little NJ feeding and no glutamine supplementation. These data are displayed in Table 1 .
At discharge the range of BWL was from ϩ1.5 to Ϫ11.2 (mean Ϫ4.5%) in 14 patients. Of the eight who kept the tube in until engraftment, the range of BWL was Ϫ1.4 to Ϫ6.8 (mean Ϫ4.43%). Of the six with weight data who lost their tubes early, the range was ϩ1.5 to Ϫ11.2 (mean Ϫ4.58%). The difference was not significant.
At 3 months the range of BWL in the nine patients still alive was from ϩ2.3 to Ϫ19.1 (mean Ϫ9.1%). Of the five remaining who kept the tube in, the range of BWL was Tx ϭ transplant; D/C ϭ discharge.
ϩ2.3 to Ϫ18 (mean Ϫ7.46%). Of the four remaining who lost their tubes, the range of BWL was Ϫ4.8 to Ϫ19.1 (mean Ϫ11.2%). These differences were not significant. At 6 months the range of BWL in the eight patients alive was ϩ3 to Ϫ15 (mean Ϫ5.99%). Of the five who kept the tube down, the range was ϩ3 to Ϫ15 (mean Ϫ4.88%). Of the three left who lost the tube, the range was Ϫ1.2 to Ϫ15 (mean Ϫ7.83%). Again, these differences are not significant.
Outcome of pilot group
At discharge, 14/15 (93%) of the total group were alive with 8/8 (100%) of the fed group and 6/7 (86%) of those that lost their tubes early.
At 3 months, 9/15 (60%) of the total group were alive with 5/8 (62.5%) of the fed group and 4/7 (57%) of those that lost their tubes early.
At 6 months, 8/15 (53%) of the total group were alive with 5/8 (62.5%) of the fed group and 3/7 (43%) of those that lost their tubes early.
Bone Marrow Transplantation
Discussion
Adequate nutritional intake is important to reduce the risks of morbidity and mortality associated with malnutrition in the bone marrow transplant patient. It may have a direct relationship to non-relapse outcome 21, 22 and the overall cost of post-transplant care. 23 The timing, route and composition of feed to use are as yet unclear.
This pilot study shows that Bengmark NJ tubes are a safe and effective method of feeding BMT patients. The tube was well tolerated by the majority (87%) of patients. Tubes were lost in 47% of patients and the reasons for this have been identified and can be corrected in most instances. When a NJ tube is in position there is often a redundant loop in the stomach. When patients vomit, this loop is often brought up through the mouth, although the distal end remains post pylorus. If the tube has been secured at the nose, as is standard practice with NG tubes, the vomited loop is clearly distressing for the patient and results in tube removal. However, if the tubes are allowed to be free at the nose but secured with tape at the cheek, 5-10 cm of tube may come out the nose during vomiting, will not cause distress and when vomiting has ceased, will pass spontaneously again. Vomiting can be quite forceful during induction conditioning therapy. Every effort is made to provide a successful anti-emetic regimen, but tube loss is high during this time. It may be more appropriate to defer the placement of NJ tubes, and thus feeding, until day ϩ1, which would be after induction chemoradiation, but before pancytopenias and mucositis develop.
There were no significant differences in terms of weight loss between the fed group and those that lost their tubes early. It was interesting to note that 5/9 (56%) of the patients with weight data available at 3 months, weighed less than at discharge. At 6 months 6/8 (75%) patients with weight data still weighed less than pre-transplant. This suggests that many patients might benefit from continued feeding post engraftment and discharge.
Survival and engraftment data are difficult to analyse in such a small group. However, there was no significant difference in survival or time to engraftment between the two groups.
During the pilot study the NJ tubes were occasionally used for drug administration, thus providing a useful way of continuing oral medication in a group who often require intravenous medication during periods of severe mucositis. This is obviously a potential additional cost-saving which could be associated with enteral access. Further work is needed to ensure that medication given directly into the jejunum is adequately absorbed and that flush protocols are effective at preventing tube blockage following drug administration via feeding tubes.
In conclusion, NJ Bengmark tubes are a safe and effective method of feeding BMT patients and are easily inserted before conditioning with a well motivated multi-disciplinary nutritional team. Alterations in tube fixing may improve the lifetime of each tube although loss due to forceful vomiting remains a problem. Delaying tube insertion to day ϩ1 could solve this.
Having shown that it is possible to achieve and maintain enteral access in these patients, a randomised, multi-centre trial looking at clinical outcomes, costs, severity of gut damage and nutritional benefit in patients undergoing allogeneic BMT is planned. We hope to compare elective NJ feeding, elective PN and our standard approach of a fortified diet 'salvage' PN.
